SCM
EWTX icon

Sterling Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Sterling Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.2K Sell
251
-187
-43% -$6.45K ﹤0.01% 2203
2026
Q1 		$13.8K Sell
438
-10
-2% -$288 ﹤0.01% 2204
2025
Q4 		$11.1K Buy
448
+285
+175% +$5.72K ﹤0.01% 2551
2025
Q3 		$2.64K Sell
163
-8
-5% -$113 ﹤0.01% 2936
2025
Q2 		$2.24K Buy
171
+96
+128% +$1.38K ﹤0.01% 2890
2025
Q1 		$1.65K Hold
75
– – ﹤0.01% 2661
2024
Q4 		$2K Hold
75
– – ﹤0.01% 2785
2024
Q3 		$2K Buy
+75
New +$1.49K ﹤0.01% 2185

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sterling Capital Management's EWTX Position: Q2 2026 in Review

Sterling Capital Management reduced its Edgewise Therapeutics (EWTX) stake by 43% in Q2 2026, selling an estimated $6.45K and leaving 251 shares worth $10.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2203.

Sterling Capital Management first reported a position in EWTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $13.8K in Q1 2026. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Sterling Capital Management held 251 shares of Edgewise Therapeutics worth $10.2K as of Q2 2026.
  • Sterling Capital Management sold 187 Edgewise Therapeutics shares in Q2 2026, an estimated $6.45K.
  • Edgewise Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2203 holding.
  • Sterling Capital Management first reported a position in Edgewise Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Edgewise Therapeutics position peaked at $13.8K in Q1 2026.
  • 225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.